The Week

DexCom (DXCM) fell 3.22% this week to close at $87.90, down from a prior close of $90.82. The S&P 500 rose 0.09%, leaving the stock roughly 3.31 percentage points behind the benchmark. The move was not a straight line down. Monday (31 Aug) opened at $90.00 and closed at $91.06, and Tuesday (1 Sep) touched the week’s high of $92.335. The stock then drifted lower over the next three sessions, with Friday (4 Sep) opening at $88.78 and printing a low of $87.65 before finishing at $87.90. Weekly amplitude came to 5.21%.

Key Events

This week’s news centred on conference schedules and sector narratives rather than product or financial updates. On 1 Sep, reports linked DexCom’s global expansion momentum to the investment case, and the company was also mentioned in a broader digital health discussion. Later the same day, DexCom confirmed it would present at the Wells Fargo annual healthcare conference. A market recap on 2 Sep noted the stock fell on the day but still outperformed competitors. There were no direct events from earnings, regulation or product announcements.

Analyst Ratings

Across 29 institutions covering DexCom, 22 assign a buy and 3 assign an overweight rating, while 3 are at hold and 1 has no opinion; none rate it underweight or sell. The consensus rating is strong buy, with a consensus target of $94.12, about 7.08% above the latest price of $87.90. Individual targets range from $79.00 to $115.00, which points to a fairly wide spread of views. Within the medical devices industry, DexCom ranks 5th out of 142 names on ratings.

The Week Ahead

No DexCom earnings are scheduled for next week, but the macro calendar is busy. On Tuesday 8 Sep, the US NFIB small business optimism index is due, with a prior reading of 99.8. Thursday 10 Sep brings initial jobless claims, final demand PPI, core PPI excluding food and energy, existing home sales annualised and wholesale sales. PPI forecasts tend to sit above prior readings. Treasury auction results also land on 10 Sep. For a higher-valuation medical device name like DexCom, shifts in rate and inflation expectations could influence risk appetite.

In Short

DexCom pulled back this week, even as the consensus rating stays at strong buy and the consensus target sits about 7.08% above spot. Ratings also rank near the front of the medical devices peer group. Valuation is not cheap, with a P/E around 33x and P/B around 12.65x. The latest session’s money flow shows retail-side activity running much larger than institutional-side flow, with limited directional signal. The next test lies in a crowded macro schedule—PPI prints and the 10-year auction—alongside any product clues from the Wells Fargo healthcare conference.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.